3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
6
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Small Cell Lung Carcinoma
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
71
Carboplatin
68
Paclitaxel
57
Radiotherapy
43
Specimen Handling
37
Gemcitabine
36
Erlotinib Hydrochloride
32
Etoposide
30
Magnetic Resonance Spectroscopy
29
Docetaxel
28
Taxes
27
Pemetrexed
23
Platinum
20
Vinorelbine
19
1,2-diaminocyclohexaneplatinum II citrate
19
Bevacizumab
18
Cyclophosphamide
16
Biopsy
16
Radiation
15
pembrolizumab
14
Immunoglobulin G
12
Disulfides
12
Topotecan
11
Gefitinib
11
durvalumab
9
atezolizumab
9
aldesleukin
9
Nivolumab
9
Irinotecan
9
Bortezomib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Diagnostic Imaging
×
Thoracic
×
Clear all
NCT00047385
2014-05-20
NLST
National Cancer Institute (NCI)
Phase 3
Completed
53,454 enrolled
15 charts